![]() |
市场调查报告书
商品编码
1519991
全球蛋白质晶片市场 2024-2031Global Protein Chip Market 2024-2031 |
按类型(分析微阵列、功能蛋白微阵列和反相蛋白微阵列)、按应用(抗体表征、临床诊断和蛋白质组学)和最终用途(製药和生物技术公司)分類的蛋白质晶片市场规模、份额和趋势分析报告、学术和研究机构、诊断实验室以及医院和诊所),预测期(2024-2031)
预计蛋白质晶片市场在预测期内(2024-2031)将以 6.4% 的复合年增长率成长。蛋白质晶片,也称为蛋白质微阵列,是蛋白质体学中使用的一种高通量技术,用于在单一实验中并行检测和定量多种蛋白质。它由固体表面(通常是玻片或硅晶片)组成,其上以阵列形式固定有特定的捕获分子(例如抗体、胜肽或蛋白质)。支持蛋白质微阵列市场成长的主要因素是对个人化医疗和精准诊断、技术投资和创新的需求不断增长。
Protein Chip Market Size, Share & Trends Analysis Report by Type (Analytical Microarrays, Functional Protein Microarrays, and Reverse Phase Protein Microarrays), by Application (Antibody Characterization, Clinical Diagnostics, and Proteomics), and by End-Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Diagnostic Laboratories and Hospitals & Clinics), Forecast Period (2024-2031)
Protein chip market is anticipated to grow at a CAGR of 6.4% during the forecast period (2024-2031). A protein chip, also known as a protein microarray, is a high-throughput technology used in proteomics for the parallel detection and quantification of multiple proteins in a single experiment. It consists of a solid surface, typically a glass slide or a silicon chip, onto which specific capture molecules such as antibodies, peptides, or proteins are immobilized in an array format. Major factors supporting the protein microarray market growth are the increasing demand for personalized medicine and precision diagnostics, technological investments, and innovations.
Market Dynamics
Advancements in Protein Chip Technology: Revolutionizing Proteomics and Diagnostics
Technological advancements in protein chip technology have revolutionized the field of proteomics research and clinical diagnostics. These advancements encompass improvements in microarray fabrication, surface chemistry, and detection methods, leading to enhanced sensitivity, specificity, and multiplexing capabilities of protein chips. Advanced protein chip platforms enable the simultaneous analysis of thousands of proteins from complex biological samples, facilitating biomarker discovery, drug target identification, and pathway analysis with unprecedented speed and accuracy. These technological innovations drive the development of novel protein chip assays tailored for various research and clinical applications, fueling the growth of the global protein chip market. For instance, in December 2023, Theralink Technologies announced groundbreaking research conducted in collaboration with George Mason University and the University of California, San Francisco. Through the ISPY-2 trial, tumors from over 700 breast cancer patients were evaluated using Reverse Phase Protein Array (RPPA), uncovering novel therapeutic avenues for challenging breast cancers.
The Role of Protein Chips in Personalized Healthcare
Growing demand for personalized medicine is a significant driver shaping the trajectory of the global protein chip market. Personalized medicine aims to provide tailored therapeutic interventions based on individual patient characteristics, including genetic makeup, proteomic profile, and environmental factors. Protein chips play a crucial role in personalized medicine by enabling the identification of disease biomarkers, molecular signatures, and treatment responses at the molecular level. By analyzing protein expression patterns and signaling pathways in patient samples, protein chips empower clinicians to make informed decisions regarding patient care, treatment selection, and disease management strategies. As personalized medicine gains prominence in healthcare, the demand for protein chips as essential tools for molecular profiling and precision diagnostics continues to grow, driving market expansion and diversification of product offerings.
Market Segmentation
Functional Protein Microarrays is Projected to Emerge as the Largest Segment
The functional protein microarrays segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes its versatility and utility in high-throughput protein analysis. Functional protein microarrays enable the simultaneous screening of thousands of protein interactions, protein-protein binding events, enzyme activities, and post-translational modifications in a single experiment. This high-throughput capability accelerates the discovery of novel protein functions, biomarkers, drug targets, and therapeutic compounds, facilitating advancements in basic research, drug development, and clinical diagnostics.
Clinical Diagnostics Segment to Hold a Considerable Market Share
The clinical diagnostics segment holds a considerable market share due to its critical role in advancing personalized medicine and precision diagnostics. Protein chips are increasingly utilized in clinical settings for the rapid and accurate detection of various diseases, including cancer, cardiovascular disorders, infectious diseases, and neurological conditions. By analyzing protein expression patterns and identifying disease-specific biomarkers, protein chips enable clinicians to diagnose diseases at early stages, predict treatment responses, and monitor disease progression with high sensitivity and specificity. For instance, in November 2023, Octave Bioscience, Inc. secured a $10.0 million grant from The Michael J. Fox Foundation to develop a multi-analyte protein biomarker test for Parkinson's disease, aiming to improve disease assessment.
The global protein chip market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Empowering Precision Healthcare: Asia-Pacific's Rise in the Protein Chip Market
Asia-Pacific emerges as the fastest-growing market in the global protein chip sector due to several key drivers. The region's significant investments in healthcare infrastructure and research capabilities, propelled by economic expansion and government initiatives, foster the adoption of advanced technologies like protein chips. With a large and diverse population, including many affected by chronic and infectious diseases, Asia-Pacific offers a substantial market for protein-based diagnostic solutions, fueling demand for protein chips. Moreover, the region's increasing focus on precision medicine and personalized healthcare, coupled with collaborations between local and international players, further propels market growth. For instance, in February 2023, Sengenics introduced KREXTM technology to address challenges in efficiently producing fully functional proteins for clinical diagnostics, vaccine development, and drug discovery. Utilizing Biotin Carboxyl Carrier Protein (BCCP), this innovation enhances protein folding and solubility, enabling high-throughput expression of correctly folded proteins. Technology facilitates the simultaneous evaluation of numerous mutant proteins, offering insights into potential therapeutic interventions.
North America Holds Major Market Share
Among all the regions, North America holds a significant share due to its robust healthcare infrastructure, research ecosystem, and leading pharmaceutical companies drive substantial demand for protein chips in applications like drug discovery and personalized medicine. Additionally, the region's emphasis on healthcare innovation and technological advancement, coupled with favorable government initiatives and funding support, further propels the market growth. With a large patient population, particularly those with chronic diseases, North America presents significant opportunities for protein-based diagnostic solutions. For instance, in January 2024, Agilent Technologies unveiled the ProteoAnalyzer system, an innovative automated parallel capillary electrophoresis system designed for protein analysis. This platform enhances efficiency and simplifies the analysis of complex protein mixtures, benefiting various sectors including pharmaceuticals, biotechnology, and academic research.
The major companies serving the global protein chip market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., and Randox Laboratories Ltd., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance, in January 2022, Illumina collaborated with SomaLogic to integrate the SomaScan Proteomics Assay into Illumina's high-throughput next-generation sequencing (NGS) platforms. This partnership aims to cater to the rapidly expanding high-throughput proteomics market, facilitating significant scientific discoveries within the research community.